The Patent Finder

Urogen Pharma Ltd.

17 patents currently held · Updated Nov 21, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Theracoat Ltd. (to 2015)

2
Ending by 2030
Feb 2030
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 30, 2026
    The maintenance fee for Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration (US 9,066,940) comes due Dec 30, 2026. Unpaid by Jun 30, 2027, it lapses early.
  • 1 fee due Feb 18, 2027
    The maintenance fee for Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration (US 9,107,919) comes due Feb 18, 2027. Unpaid by Aug 18, 2027, it lapses early.
  • 3 fees due May 3 to 12, 2027 · next May 3

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 23, 2026
  • 2 terms have ended since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,107,919Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration
In force
 · High confidence
In forceHigh confidence
US 9,066,940Pharmaceutical Compositions Comprising Imidazoquinolin(AMINES) and Derivatives Thereof Suitable for Local Administration
In force
 · High confidence
In forceHigh confidence
US 9,040,074Material and Method for Treating Internal Cavities
In force
 · High confidence
In forceHigh confidence
US 9,950,069Material and Method for Treating Internal Cavities
In force
 · High confidence
In forceHigh confidence
US 10,039,832Material and Method for Treating Internal Cavities
In force
 · High confidence
In forceHigh confidence
US 10,471,150Material and Method for Treating Internal Cavities
In force
 · High confidence
In forceHigh confidence
US 9,173,936Phospholipid Drug Analogs
In force
 · Low confidence
In forceLow confidence
US 9,180,183Phospholipid Drug Analogs
In force
 · Low confidence
In forceLow confidence
US 9,540,407Phospholipid Drug Analogs
In force
 · Low confidence
In forceLow confidence
US 9,801,854Slow Release Formulations of Cell Cycle Regulators and Anti-Cancer Agents for Local Treatment of Solid Cancer
In force
 · High confidence
In forceHigh confidence
10 of 17 patents shown.
Pro members see all 17.
Pro members: see all 17 patents
Also on record, not counted in the 17: 2 lapsed for an unpaid fee · 6 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 13 abandoned

Showing 1 to 10 of 14, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
19/094,915Immunomodulating Treatments of Body CavitiesMar 30, 2025Pending
18/374,645Compositions Comprising a Thermoreversible Hydrogel, and Having an Extended In-Use PeriodSep 28, 2023Abandoned
18/129,543Material and Method for Treating Internal CavitiesMar 31, 2023Abandoned
18/129,508Material and Method for Treating Internal CavitiesMar 31, 2023Abandoned
18/129,497Material and Method for Treating Internal CavitiesMar 31, 2023Abandoned
18/180,152Immunomodulating Treatments of Body CavitiesMar 8, 2023Abandoned
17/566,882Material and Method for Treating Internal CavitiesDec 31, 2021Abandoned
17/006,926Immunomodulating Treatments of Body CavitiesAug 31, 2020Abandoned
16/593,297Pharmaceutical Compositions Comprising Imiquimod for Use in the Treatment of Carcinoma in Situ of the BladderOct 4, 2019Abandoned
16/518,511Material and Method for Treating Internal CavitiesJul 22, 2019Abandoned
10 of 14 applications shown.
Pro members see all 14 published applications.
Pro members: see all 14 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited